Milnacipran: Phase III data

In the double-blind, placebo-controlled, North American Phase III MLN-MD-03 trial in 1,025 subjects with FMS, 100 mg milnacipran met the 2

Read the full 217 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE